申请人:EURO-CELTIQUE S.A.
公开号:EP1942106A1
公开(公告)日:2008-07-09
Compounds of formulae (I) and (II) where X is S or O and Ar2, R1, R2, R3, R8 n, m, and t are disclosed herein, or a pharmaceutically acceptable salt thereof (a "3-substituted Pyridyl Compound"), compositions comprising an effective amount of a 3-substituted Pyridyl Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a 3-substituted Pyridyl Compound are disclosed herein.
本文公开了式(I)和(II)化合物,其中 X 为 S 或 O,Ar2、R1、R2、R3、R8 n、m 和 t 为其或其药学上可接受的盐("3-取代
吡啶基化合物")、包含有效量 3-取代
吡啶基化合物的组合物,以及治疗或预防疼痛、尿失禁、溃疡、炎症性肠病、肠易激综合征、成瘾性疾病、帕
金森病、焦虑症、癫痫、帕
金森病、帕
金森病、帕
金森病、帕
金森病、帕
金森病、帕
金森病、帕
金森病、帕
金森病、帕
金森病、帕
金森病、帕
金森病、帕
金森病、帕
金森病帕
金森病、焦虑症、癫痫、中风、癫痫发作、瘙痒症、精神病、认知障碍、记忆缺陷、脑功能受限、亨廷顿舞蹈症、肌萎缩性脊髓侧索硬化症、痴呆症、视网膜病变、肌肉痉挛、偏头痛、呕吐、运动障碍或动物抑郁症的方法,包括向有需要的动物施用有效量的 3-取代
吡啶基化合物。